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Background. Vaccination with synthetic long peptides (SLP) is a promising new treatment strategy for chronic hepatitis B virus 
(CHB). SLP can induce broad T-cell responses for all HLA types. Here we investigated the ability of a prototype HBV-core (HBc)-
sequence-derived SLP to boost HBV-specific T cells in CHB patients ex vivo.
Methods. HBc-SLP was used to assess cross-presentation by monocyte-derived dendritic cells (moDC) and BDCA1+ blood my-
eloid DC (mDC) to engineered HBV-specific CD8+ T cells. Autologous SLP-loaded and toll-like receptor (TLR)-stimulated DC were 
used to activate patient HBc-specific CD8+ and CD4+ T cells.
Results. HBV-SLP was cross-presented by moDC, which was further enhanced by adjuvants. Patient-derived SLP-loaded moDC 
significantly increased autologous HBcAg18-27-specific CD8+ T cells and CD4+ T cells ex vivo. HBV-specific T cells were functional 
as they synthesized tumor necrosis factor-alpha and interferon-gamma. In 6/7 of patients blockade of PD-L1 further increased SLP 
effects. Also, importantly, patient-derived BDCA1+ mDC cross-presented and activated autologous T-cell responses ex vivo.
Conclusions. As a proof of concept, we showed a prototype HBc-SLP can boost T-cell responses in patients ex vivo. These results 
pave the way for the development of a therapeutic SLP-based vaccine to induce effective HBV-specific adaptive immune responses 
in CHB patients.
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About one-third of the world’s population is exposed to hepati-
tis B virus (HBV) during their lifetime. Although most people 
effectively clear the virus, chronic HBV (CHB) still affects about 
250 million people worldwide [1]. Because effective therapy is 
lacking, yearly around 1 million people die of HBV-related liver 
failure, liver cirrhosis, and liver cancer [2]. Therefore, there is a 
high need for more effective therapy to treat CHB.
CD8+ cytotoxic T lymphocytes play a crucial role in viral 
defense by directly killing virus-infected cells and by produc-
ing antiviral cytokines. CD4+ helper T cells facilitate induc-
tion of optimal and long-lasting CD8+ T-cell responses and 
exert antiviral effector function themselves [3, 4]. In contrast 
to HBV-resolvers, chronic patients have very few functional 
HBV-specific T cells, and this is thought to be responsible for 
viral persistence [5, 6]. Previous studies on bone marrow and 
liver transplantation demonstrated that CHB infection can be 
cleared by a fully functional immune system, which supports 
the concept that therapeutic restoration of antiviral immunity 
in chronic patients could lead to disease resolution.
Dendritic cells (DC) play a crucial role in inducing T-cell 
responses. DC have the unique capacity to present exogenous 
antigens not only in MHC class  II to activate CD4+ T cells, 
but also to digest these antigens into short peptides and pres-
ent them in MHC class  I  to activate CD8+ T cells, a process 
called cross-presentation [7]. Synthetic long peptides (SLP) are 
designed to make use of these unique capacities of DC to boost/ 
induce T-cell responses, and have already been very effective in 
patients that suffer from HPV-induced (pre)malignant lesions 
[8], metastatic colorectal cancer [9], or ovarian cancer [10]. SLP 
are typically, and most optimally, 20–45 amino acids in length 
and contain epitopes for both CD8+ and CD4+ T cells, the lat-
ter facilitating optimal, long-lasting CD8+ T-cell responses 
[11]. For SLP, in contrast to short peptides or DNA, presen-
tation of viral peptides by nonprofessional antigen presenting 
cells is excluded. Importantly, in vivo presentation of epitopes 
from SLP by DC was more efficient and longer lived than from 
whole protein [11]. Adjuvants can further improve SLP vac-
cines by enhancing the immune response [12] and importantly 
are required to prevent the induction of tolerance upon naive 
T-cell priming. Toll-like receptor 2 (TLR2) ligands boosted the 
effectiveness of ovalbumin- and murine leukemia virus-based 
SLP in mice and HPV-based SLP in humans [12, 13]. Also, 
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TLR3 ligands have particular potential to aid antiviral immune 
responses because TLR3 is highly expressed in myeloid DC sub-
sets with high cross-presenting capacities [14].
Finally, for immunotherapy development it is essential to 
consider the suppressive immune context in CHB patients. The 
immune system in these patients is worn out by chronic infec-
tion and continuous antigen exposure. As a result, DC func-
tion can be impaired [14, 15] and HBV-directed T cells may be 
exhausted [16, 17]. Animal models for chronic viral infections 
(including HBV) demonstrated that blocking PD-1/ PD-L1, as 
typical molecules related to exhaustion, can enhance vaccine 
success [18].
We hypothesize that SLP vaccination, with or without addi-
tional immune modulation, can ultimately induce HBV-specific 
immune responses leading to full viral elimination, thereby pre-
venting fatal liver disease. Therefore, we designed a prototype SLP, 
based on HBV core protein (HBcAg). Using this SLP, we inves-
tigated the ability of CHB patient DC to (cross-)present and to 
stimulate autologous HBV-specific T cells ex vivo. Additionally, 
the effect of adjuvants and PD-L1/PD-1 blockade were examined. 
Our results demonstrate that the prototype HBc-SLP can boost 
HBV-directed T-cell responses ex vivo, putting forward SLP-
based vaccination as a promising treatment strategy for CHB.
MATERIALS AND METHODS
All detailed information about material and methods is provided 
in the section Supplementary Methods.Prototype hepatitis B 
virus (HBV)-derived synthetic long peptide (SLP) cross-pre-
sented by autologous dendritic cells boosted HBV-specific 
(CD4,CD8) T-cell responses in chronic HBV (CHB) patients 
ex vivo. Often, PD-L1 blockade improved SLP-responses. This 
supports therapeutic SLP-based vaccine development for CHB 
treatment.
RESULTS
Efficient Cross-Presentation by Human moDC Loaded With SLP
We designed a prototype HBc-SLP of 37 amino acids long, a 
sequence derived from the conserved region of HBV genotype 
A, including the immunodominant HLA-A*02 restricted CD8+ 
T-cell epitope HBcAg18-27, and 2 other published CD8+ T-cell 
epitopes and 3 CD4+ epitopes (Figure 1A).
To visualize antigen presentation by DC, we generated a novel 
HBcAg18-27-specific CD8+ T-cell readout system by retroviral trans-
duction of the HBcAg18-27 cognate T-cell receptor (TCR), described 
by Gehring et al, into a CMV-pp65495-503-specific CD8+ T-cell clone 
with high expansion capacity and functionality (Supplementary 
Figure 1A, B) [19]. Having confirmed the sensitivity of the generated 
HBcAg18-27recognizing CD8+ T cells (Supplementary Figure 1C), we 
tested the ability of SLP-loaded DC to present the HBcAg18-27 epi-
tope. SLP-loaded moDC induced interferon-gamma (IFN-γ) pro-
duction by HBcAg18-27-specific CD8+ T cells in all donors, indicating 
the epitope was readily processed and cross-presented (Figure 1B). 
Dose titration revealed that IFN-γ production increased with higher 
SLP concentrations. Optimal cross-presentation was reached at a 
concentration of 10—20 µM HBc-SLP (Figure 1B). At higher SLP 
concentrations, T-cell activation again decreased, likely by a nega-
tive effect of the solvent dimethyl sulfoxide (DMSO) on DC func-
tion (not shown). Presentation of HBcAg18-27 by SLP-loaded DC 
increased with time, whereas presentation of short HBcAg18-27 pep-
tide did not (Figure 1B).
To demonstrate that release of the HBcAg18-27 epitope from HBc-
SLP depended on intracellular processing by moDC, we inhibited 
intracellular protein transport or the proteasome. Blocking trans-
port of peptide/MHC-I complexes from endoplasmic reticulum to 
the cell surface with Brefeldin A resulted in a significant reduction 
in SLP cross-presentation (Figure 1C). Also a significant reduction 
was observed by the proteasome inhibitor epoxomicin (Figure 1C). 
As expected, presentation of HBcAg18-27 short peptide, which 
does not require internalization or proteasomal processing, was 
unchanged by these inhibitors. Together these findings confirm that 
processed and subsequent cross-presentation of HBcAg18-27 epitope 
from SLP by DC required proteasome activity and intracellular 
transport. To obtain a maximum response while minimizing neg-
ative effects of DMSO, we continued with 10 µM SLP and 20 hours 
of peptide loading in following experiments.
Subsequently, we assessed whether TLR2-ligand Amplivant 
or TLR3-ligand PolyI:C enhanced cross-presentation of the SLP-
contained HBcAg18-27 epitope. Both adjuvants induced upregu-
lation of costimulatory markers CD83, CD86 (Supplementary 
Figure  2A), and cytokine production by DC (Supplementary 
Figure 2B). Concordantly, both adjuvants significantly enhanced 
SLP-induced activation of HBcAg18-27-specific CD8+ T cells in a 
dose-dependent manner (Figure 1D).
These data show that SLP are efficiently cross-presented by 
moDC and that both Amplivant and PolyI:C further enhance 
cross-presentation and activation of antigen-specific T cells.
SLP-Induced Patient-Derived HBV-Specific CD8+ T-Cell Proliferation Ex 
Vivo
To assess the potential of our SLP to boost T-cell responses in 
CHB patients, we analyzed the capacity of HBc-SLP-loaded 
patient-derived moDC to activate autologous HBV-specific T 
cells ex vivo. After coculturing patient PBLs (monocytes and 
B cell-depleted-PBMC, hereinafter referred to as PBLs. See 
Supplementary Methods) for 12 days with SLP-loaded moDC 
in the presence of Amplivant or PolyI:C, both the frequency 
(Figure  2A–C; 3.6  ±  5.3 and 2.9  ±  2.5-fold, respectively) and 
absolute numbers (Figure  2D; 4.0  ±  5.9 and 2.8  ±  2.4-fold, 
respectively) of HBcAg18-27-specific CD8+ T cells significantly 
increased compared to day 0 (Figure  2) and also compared 
to a 12-day coculture with adjuvants alone (Figure 2C, D). In 
some patients only absolute numbers, but not frequencies, of 
HBcAg18-27-specific T cells were augmented, suggesting addi-
tional proliferation of HBV-specific CD8+ T cells recognizing 
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other SLP-contained epitopes. Importantly, irrelevant HBpol502-
510-specific CD8+ T cells did not increase (Figure 2B).
Of note, obvious differences in response rate/level between 
naive patients or those treated with nucleoside analogs were 
not found (Figure  2). Taken together, we demonstrate that 
SLP-loaded patient-derived moDC can effectively expand 
autologous HBV-specific CD8+ T cells ex vivo.
Functionality of SLP-Expanded HBcAg18-27-Specific CD8+ T Cells
To determine the functionality of SLP-induced HBcAg18-27-
specific CD8+ T cells, 12-day expanded PBLs were restimulated 
with HBcAg18-27 short peptide. We identified a clear population 
of IFN-γ and tumor necrosis factor-alpha (TNF-α)- producing 
CD8+ T cells. Importantly, both frequencies and absolute num-
bers of functional T cells were significantly larger in cultures 
where SLP had been present during the expansion phase and 
this was most pronounced for multifunctional T cells express-
ing both IFN-γ and TNF-α (Figure 3A–C). The SLP effect was 
most significant for cultures with Amplivant (Figure  3). In a 
subset of experiments the effect of SLP without adjuvants 
was also tested (Supplementary Figure  3). Unexpectedly, in 
patient cell-derived cultures the effect of adjuvant was not 
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Figure 1. Cross-presentation by human monocyte-derived dendritic cells (moDC). A, Sequence of amino acids constituting the hepatitis B virus core–synthetic long peptides 
(HBc-SLP1-37). Upper (red online) lines indicate reported CD4+ T-cell epitopes, which are the HLA-DR restricted HBcAg1-20 epitope, the HLA-DR restricted HBcAg16-30 epitope, 
and the HLA-DP restricted HBcAg18-27 epitope. Lower (green online) lines indicate reported CD8+ T-cell epitopes, which are the HLA-A*02 restricted HBcAg18-27 epitope, the 
HLA-B*51 restricted HBcAg19-27 epitope, and the HLA-A*02 restricted HBcAg11-27 epitope. B, SLP dose titration and loading kinetics on moDC, read out by HBcAg18-27 CD8+ 
T-cell activation. Left panel: interferon-gamma (IFN-γ) production (by enzyme-linked immunosorbent assay, ELISA) upon coculture of in vitro engineered HBcAg18-27 CD8+ T 
cells with moDC of 3 different donors exposed to increasing concentrations of HBc-SLP. Each line represent data from a different donor. Right panel: IFN-γ production upon 
20-hour coculture of HBcAg18-27-specific T cells with moDC pulsed for indicated time points with 2 µM HBc-SLP or HBcAg18-27 short peptide. Mean ± SEM. N = 4 donors. C, 
IFN-γ production upon 20-hour coculture of engineered HBcAg18-27 specific T cells with moDC pulsed with indicated concentration of antigens in the presence or absence 
of epoxomicin or Brefeldin A. moDC were fixed with 0.2% paraformaldehyde prior to the start of coculture. Mean + SEM. N = 4 donors. IFN-γ levels were normalized to the 
amount induced by SLP only (2 µM) in each experiment. Statistical analysis based on log transformed raw data. D, IFN-γ production upon 20-hour cocultured engineered 
HBcAg18-27-specific T cells with moDC pulsed for 20 hours with HBc-SLP (10 µM) either in the absence or presence of increasing concentrations of Amplivant or PolyI:C. 
Mean ± SEM. N = 4 donors. C, D *P < .05, **P < .01 by 1-tailed paired t tests.
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Figure 2. Patient-derived HBcAg18-27-specific CD8+ T-cell induction by hepatitis B virus–synthetic long peptides (HBV-SLP) stimulation ex vivo. A, Representative tetramer 
staining of HBcAg18-27-specific CD8+ T cells in peripheral blood lymphocytes from a chronic hepatitis B virus patient before (day 0) and after 12-day culture with autologous 
monocyte-derived dendritic cells (moDC) loaded with Amplivant ± SLP (upper panels) or PolyI:C ± SLP (lower panels). B, Patient cultures as in (A) for indicated conditions, now 
comparing multimer staining for HBcAg18-27-specific CD8+ T cells and irrelevant HBpAg502-510-specific CD8+ T cells. Representative of N = 7 donors. C, Left panel: frequency 
of HBcAg18-27-specific CD8+ T cells among total CD8+ T cells before and after 12-day cultures performed as described in (A). Right panel: relative change caused by SLP in 
the frequency of HBcAg18-27-specific CD8+ T cells compared to stimulation with adjuvant alone. n = 19 for Amplivant and n = 12 for PolyI:C. D, Data as in (C) but for absolute 
HBcAg18-27-specific CD8+ T-cells numbers. Samples from 1 individual are connected by a line (C, D). Diamonds (◊) represent treatment-naive patients. * P < .05, **P < .01, 
***P < .001 by Wilcoxon signed rank test (1-tailed) on raw data. Abbreviation: AV, Amplivant.
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clear (Supplementary Figure 3), which may be due to the long 
cytokine supplemented culture protocol, the readout used, 
and/ or the relative high concentration of SLP (10 µM) used. 
Nonetheless, our experiments clearly indicate SLP can aug-
ment HBV-specific functional CD8+ T cells ex vivo.
HBc-SLP-Loaded moDC Induce Functional CD4+ T Cells
Key to SLP is that they can contain multiple CD4+ and CD8+ 
T-cell epitopes [11]. We selected patients based on HLA-A*02, 
but not on HLA class II genotype. The absence of HLA class II 
typing makes searching for specific CD4+ T-cell responses 
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Figure 3. Patient-derived functional hepatitis B virus (HBV)-specific CD8+ T-cell induction by HBV-synthetic long peptides (SLP) stimulation ex vivo. A, T cells were restim-
ulated with HBcAg18-27 peptide after an initial 12-day expansion culture by Amplivant ± SLP. Representative dot plots from an intracellular cytokine staining for interfer-
on-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) production in CD8+ T cells are shown. B, C, Summary of the mean relative (B) and absolute cell numbers (C) of 
cytokine-producing CD8+ T cells upon restimulation with HBcAg18-27 peptide after an initial 12-day expansion culture by Amplivant ± SLP and by PolyI:C ± SLP. Depicted are 
mean + SEM for 12 (Amplivant) and 6 (PolyI:C) different CHB patients. * P < .05, **P < .01, ***P < .001 by 1-tailed Wilcoxon signed rank test. Abbreviation: AV, Amplivant.
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difficult. Nonetheless, our data strongly indicated HBV-specific 
CD4+ T-cell responses were also boosted. First, total CD4+ 
T-cell numbers increased upon HBV-SLP exposure, especially 
in the presence of Amplivant (Supplementary Figure 4). More 
importantly, upon restimulation of the 12-day culture that was 
stimulated by SLP-loaded moDC with either adjuvant in the 
expansion phase, a significant increase in cytokine-produc-
ing CD4+ T cells was observed, in both frequency and abso-
lute number, compared to adjuvant alone (Figure 4). Of note, 
increase in functional CD4+ T-cell numbers were also observed 
when T cells were stimulated with SLP alone (Supplementary 
Figure  4). Again, we found no indication of differences in 
HBV-specific CD4+ T responses between untreated and treated 
patients (Figure 4).
Blockade of PD-1/PD-L1 can Further Increase the Response to SLP
Previous studies showed that antiviral responses of periph-
eral blood and intrahepatic T cells can be improved by 
blocking PD-1/PD-L1 interaction [5, 16, 20–22]. To inves-
tigate whether this also improved SLP effect, patient PBLs 
were expanded by SLP-loaded autologous moDC for 12 days 
as before, but now in the presence of PD-L1 blocking or iso-
type control antibodies. PD-L1 blockade improved CD8+ 
T-cell responses in both Amplivant and polyI:C stimulated 
cultures in 4 and 5 out of 7 patients, respectively, up to 
16-fold (Figure  5). We found no relationship between the 
effect of PD-L1 blockade and patient characteristics (eth-
nicity, age, gender), viral parameters (viral load, alanine 
aminotransferase [ALT], HBsAg), or T-cell PD-1 expres-
sion (not shown). Overall, these data demonstrate the effect 
of PD-L1 blockade was heterogeneous between patients, 
but indicate that for some patients PD-1/PD-L1 blockade 
may improve SLP vaccine efficacy.
BDCA1+ mDC Derived From HBV Patients and Healthy Controls Cross-
Present HBV-SLP to a Similar Extent and Stimulate Autologous HBcAg-
Specific T Cells Ex Vivo
Having established that patient-derived T cells can be boosted 
by HBc-SLP-loaded in vitro generated moDC, we next assessed 
whether also circulating myeloid DC (mDC) are able to effec-
tively present the SLP, because the SLP vaccine will rely on 
these cells in vivo. So far, no conclusive data exist on the effect 
of CHB infection on the cross-presenting capacity of pri-
mary mDC. Gehring et  al demonstrated a remaining ability 
of patient-derived mDC to cross-present HBsAg protein [23], 
but data directly comparing the cross-presentation capacity of 
patient mDC to healthy control-derived mDC were not shown. 
Therefore, we assessed the cross-presenting ability of primary 
BDCA1+ mDC from CHB patients, and compared them to 
cells from gender-matched healthy subjects (Supplementary 
Table  1). We selected CHB patients with low viral load and 
low serum ALT levels (Table  1) as we reasoned this patient 
population will be most suitable for initial clinical testing of SLP 
vaccine considering safety and immune fitness.
BDCA1+ mDC were loaded with SLP with or without adju-
vants and analyzed for their capacity to cross-present and 
activate HBcAg18-27-specific CD8+ T cells. Exogenous binding 
of HBcAg18-27 short peptide to HLA-A*02 resulted in similar 
activation of HBcAg18-27-specific T cells by patient and healthy 
control mDC (Supplementary Figure  5). To correct for vari-
ation between donors, T-cell responses were normalized to 
those observed after incubation of T cells with HBcAg18-27-
loaded BDCA1+ mDC of each donor in the same experiment. 
Importantly, patient-derived BDCA1+ mDC cross-presented 
HBcAg18-27 epitope from HBc-SLP equally well as those from 
healthy controls (Figure  6A). Both adjuvants significantly 
improved T-cell activation in healthy controls and patients to 
a similar extent.
Next, we tested whether SLP-loaded patient BDCA1+mDC 
are also able to activate autologous T cells. As observed for 
moDC, BDCA1+mDC loaded with SLP in the presence of 
Amplivant, induced a clear increase in HBcAg18-27-specific T 
cells as compared to day 0, and day 12 with Amplivant alone in 
3 out of 4 CHB patients (Figure 6B, C; 3.5 ± 2.7-fold).
These data demonstrate that CHB-patient DC are able to 
cross-present HBc-SLP and activate endogenous T-cell responses. 
Therefore patient mDC can be targeted by an SLP-based thera-
peutic vaccine to activate HBV-specific T cells in vivo.
DISCUSSION
Antigen-specific immunotherapy represents an attractive treat-
ment option for CHB [24]. Vaccines aiming to treat established 
disease require long-lived presentation of MHC-epitopes by 
appropriately activated DC and should induce both virus-spe-
cific CD8+ and CD4+ T-cell responses. The latter can strengthen 
and prolong CD8+ T-cell responses and also facilitate antibody 
responses [25]. One high-potential form of clinically validated 
immunotherapy is SLP-based vaccination [11]. To obtain proof 
of principle, we designed an SLP based on a stretch of HBcAg 
protein containing the HBcAg18-27 HLA-A*02 epitope and ad-
ditional CD8+ and CD4+ T-cell epitopes naturally flanking the 
HBcAg18-27 epitope. The present study provides proof of concept 
and demonstrates that SLP can be effectively cross-presented 
by patient-derived BDCA1+ mDC and that adjuvants such as 
Amplivant and PolyI:C can further enhance this. Furthermore, 
the HBc-SLP boosted functional patient HBV-directed CD4+ 
and CD8+ T-cell responses in multiple patients ex vivo, which 
could be further enhanced by PD-L1 blockade.
Apart from providing proof-of-concept for SLP-based ther-
apeutic vaccination in CHB, we generated a tool, that is dual 
specific HBcAg18-27-TCR transduced CMV-specific CD8+ T 
cells, to easily visualize (cross-)presentation by DC. Advantages 
of this novel read-out system include the high production of 
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Figure 4. Patient-derived functional HBV-specific CD4+ T-cell induction by hepatitis B virus-synthetic long peptides (HBV-SLP) stimulation ex vivo. A, After an initial 12-day 
expansion culture with either SLP + Amplivant (SLP) or Amplivant-exposed (−) moDC, cells were restimulated with SLP-loaded autologous moDC. Shown are representative 
dot plots of cytokine production by intracellular cytokine staining for interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α) production in CD4+ T cells. B, Summary 
of the mean + SEM frequency (upper row) and absolute cell numbers (lower row) of cytokine-producing CD4+ T cells from CHB patients upon restimulation of T cells with 
SLP-loaded autologous monocyte-derived dendritic cells (moDC) after an initial 12-day expansion culture by Amplivant ± SLP (n = 11) or by PolyI:C ± SLP (n = 5). C, Relative 
change in frequency and (D) absolute cell count of CD4+ cytokine producing (ie, IFN-γ + TNF-α) T cells after restimulation with SLP-loaded moDC. SLP plus adjuvant was com-
pared to adjuvant alone during initial culture phase. Samples from 1 individual are connected by a line. Diamonds (◊) represent treatment-naive patients. * P < .05, **P < .01, 
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IFN-γ by these cells upon cognate antigen recognition, and the 
possibility to expand them, which is extremely difficult with 
CHB patient-derived T-cell clones, which are often exhausted. 
Responses of these engineered T cells to endogenous CMV pre-
sented by antigen presenting cells can be a risk theoretically; 
however, cultures without exogenous antigen resulted in only 
a few experiments in detectable IFN-γ production, which was 
always clearly below conditions with HBV-antigens. Therefore, 
we can exclude a significant influence of endogenously pre-
sented CMV on our conclusions. This system can aid HBV 
research and also the study of immune responses against other 
infectious diseases and cancer.
In contrast to short peptides that can directly bind to HLA mol-
ecules, SLP require intracellular processing. Hence, presentation of 
SLP-derived epitopes is restricted to professional antigen presenting 
cells, such as DC. Bystander cells that are not equipped to deliver 
the necessary signals for proper T-cell activation and therefore 
can induce tolerance to presented antigens, cannot process SLP 
and extract the contained epitopes [11, 25]. Furthermore, SLP are 
able to induce polyclonal CD8+ T-cell responses because they can 
harbor several epitopes. Moreover, as opposed to short peptides, 
SLP can contain epitopes for multiple HLA alleles. Therefore SLP 
vaccines can be designed to accommodate most of the population.
Studies using HBcAg18-27 short peptide to stimulate peripheral 
cognate CD8+ T cells from CHB patients with low viral load and 
ALT, have shown variable responses after 10–14 days expansion 
in vitro, ranging from 0.01% to 14.9% of total CD8+ T cells [5, 
20, 21, 26, 27]. Effects on absolute T-cell numbers were barely 
reported. In our study, SLP-induced frequencies varied between 
0.02% and 6.56% of total CD8+ T cells. The lower HBcAg18-27-
specific CD8+ T-cell frequency may be at least in part explained 
by the fact that SLP-loaded moDC probably present a variety 
of epitopes, resulting in competition for the presentation of 
HBcAg18-27 epitope, but allowing also other HBc-specific T cells 
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Figure 5. PD-L1 blockade further boosts expansion of synthetic long peptides (SLP)-induced hepatitis B virus (HBV)-specific T cells. A, Representative dot plots of flow 
cytometric analyses of HBcAg18-27-specific CD8+ T cells from a chronic HBV (CHB) patient before (day 0) and after a 12-day expansion culture by PolyI:C ± SLP, either in the 
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Figure 6. Patient- and healthy control-derived BDCA1+ myeloid DC (mDC) cross-present hepatitis B virus-synthetic long peptides (HBV-SLP) and stimulate autologous 
HBcAg-specific T cells. A, Interferon-gamma (IFN-γ) production (by enzyme-linked immunosorbent assay, ELISA) upon 20-hour coculture of engineered HBcAg18-27-specific 
CD8+ T cells with BDCA1+ mDC from chronic hepatitis B virus (CHB) patients (n = 7) or healthy controls (n = 5) pulsed with SLP ± adjuvant or adjuvant alone for 20 hours. 
For each donor, data were normalized to IFN-γ levels produced in cocultures with BDCA1+ mDC loaded with short HBcAg18-27 peptides (see also Supplementary Figure 5). 
Each symbol represents a donor. Mean ± SEM. *P < .05, **P < .01, ***P < .001 by 1-tailed paired t tests on log transformed raw data. B, Representative tetramer staining 
of HBcAg18-27-specific CD8+ T cells in peripheral blood lymphocytes from a CHB patient before and after 12-day culture with autologous BDCA1+mDC loaded with SLP + 
Amplivant (AV), or Amplivant only. C, Left panel: absolute numbers of HBcAg18-27-specific CD8+ T cells before and after 12-day cultures as described in (B). Each line represents 
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to respond. We observed no differences between Amplivant and 
PolyI:C in CD8+ T-cell induction. This is not surprising because 
we also observed that addition of an adjuvant does not improve 
the in vitro response (Supplementary Figure 3). Furthermore, 
although the HBcAg-derived SLP successfully expanded autol-
ogous HBcAg18-27-specific CD8+ T cells in most patients, it 
should be noted that the HBcAg18-27 epitope does not bind all 
HLA-A*02 subtypes equally well [28, 29]. It binds best to HLA-
A*0201 but poorly to HLA-A*0203 [30]. Because we selected 
our patients by using pan-HLA-A*02 antibodies, the response 
in some patients may have been subject to a suboptimal HLA-
A*02 subtype.
Aside from CD8 epitopes, SLP can also cover a wide range 
of CD4 epitopes for multiple HLA alleles. The simultaneous 
induction of CD4+ T cells facilitates generation of powerful and 
long lasting CD8+ T-cell responses [3, 4]. Despite the fact that 
we did not include HLA class  II typing of our CHB patients, 
CD4+ epitopes for multiple HLA II alleles were present in the 
SLP. Concordantly, we detected SLP-driven proliferation of 
CD4+ T cells (ie, an increase in absolute numbers) and cytokine 
production in most patients.
Optimal maturation of DC is important for an effective (SLP)
vaccine and to exclude the induction of tolerance. TLR ligands 
are generally well known for their capacity to boost T-cell 
Table 1. Characteristics of Chronic HBV Patients Included in the Study
Patient number
Viral load (IU/ 
mL) ALT (IU/L) HBeAg Fibrosis Genotype Ethnicity Current treatment Gender Age (y)
T-cell proliferation 
assay in 
 Figures 2–5
pt8 2.0E1 17 neg F0-F1 C Asian Entecavir M 53
pt9 4.8E3 47 neg F0 A African Tenofovir M 29
pt10 4.0E1 54 neg F2 D Caucasian Tenofovir M 52
pt11 2.0E1 19 neg F0-F1 B Asian Entecavir M 46
pt12 2.0E1 8 neg F0 D Turkey Entecavir F 48
pt13 2.0E1 49 neg F0-F1 A African Tenofovir M 39
pt14 2.0E1 16 neg F1-F2 B Asian Entecavir F 31
pt15 2.0E1 17 neg F0 C Asian Entecavir M 56
pt16 2.0E1 14 neg F0 A&G Caucasian Entecavir M 59
pt17 2.0E1 36 neg F0-F1 A Caucasian Tenofovir M 26
pt18 2.0E1 11 neg F0-F1 n.d. African Tenofovir M 56
pt19 1.0E1 49 neg F0-F1 n.d. African Naive M 54
pt20 3.1E2 21 neg F1 n.d. Asian Naive F 49
pt21 4.2E0 59 neg F0-F1 n.d. Turkey Lamivudine M 31
pt22 3.1E2 26 neg F0-F1 D Caucasian Naive F 59
pt23 1.4E2 33 neg F0-F1 E African Naive M 37
pt24 2.5E2 44 neg F1 n.d. Asian Naive F 41
pt25 2.0E1 26 pos F0-F1 G Asian Tenofovir M 40
pt26 2.0E1 24 pos F0-F1 D Asian Tenofovir M 34
pt27 8.0E3 25 neg F0-F1 A Caucasian Naive F 46
pt28 2.0E1 22 neg F2 C Asian Entecavir F 48
pt29 5.5E2 29 neg F0-F1 n.d. Caucasian Treated before M 48
pt30 1.5E2 30 neg  F1 n.d. Asian Treated before F 63
pt31 2.0E1 17 neg F0-F1 n.d. Asian Entecavir M 47
pt32 2.0E1 22 neg F2 D Caucasian Entecavir F 62
pt33 2.0E1 25 neg F0-F1 n.d. Asian Tenofovir F 48
pt34 2.0E1 17 neg F0-F1 A Caucasian Tenofovir F 55
pt35 4.0E1 21 neg F2 n.d. Asian Entecavir M 61
BDCA1+mDC 
cross-presenta-
tion experiment 
in Figure 6A
pt1 4.1E4 55 neg F1-F2 n.d. African Tenofovir M 29
pt2 2.0E1 19 neg F0-F1 B Asian Entecavir M 45
pt3 2.0E1 27 neg F0-F1 D Asian Entecavir M 54
pt4 2.0E1 16 neg F0-F1 n.d. African Naive F 28
pt5 2.9E2 17 neg F0-F1 A African Entecavir M 51
pt6 2.6E3 26 pos F0 B Asian Tenofovir F 30
pt7 1.9E2 100 pos F1-F2 D Asian Tenofovir M 43
T-cell prolifera-
tion assay in 
Figure 6B, C
pt36 1.8E3 19 neg F0-F1 n.d. Asian Treated before F 36
pt37  2.5E1 25 neg F0 D Asian Treated before M 33
pt38 2.8E4 46 neg F2 n.d. Asian Treated before M 35
pt39 2.0E1 17 neg F0-F1 n.d. African Tenofovir M 58
M, male; F, female; n.d., not determined; ALT, alanine aminotransferase. Typically the range for normal ALT is between 7 and 56 units per liter.
Naive = never treated.
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responses in vivo [31, 32]. Each TLR ligand triggers a unique 
DC maturation program, resulting in a specific combination of 
molecules that delivers signals for antigen presentation, costim-
ulation, and T-cell function. Therefore, it is essential to offer 
SLP with the right adjuvant to steer the immune response in 
the right direction and to prevent induction of peripheral tol-
erance. In mice, TLR2 ligands were effective in inducing both 
DC maturation and CD8+ T-cell activation [13, 33]. Also, in 
human SLP studies, TLR2 ligation was very effective in facil-
itating both CD4+ and CD8+ T-cell responses [12]. PolyI:C is 
an interesting alternative because of its reported effectiveness 
in activating myeloid DC subsets with cross-presenting abilities 
[14, 34]. In our study, both adjuvants enhanced cross-presen-
tation of moDC and BDCA1+mDC to activate engineered T 
cells. Unexpectedly, addition of Amplivant to SLP did not fur-
ther increase the number of HBV-specific T cells in patient-de-
rived culture compared to SLP alone and also not much more 
functional T cells were observed. To study the additive effect of 
adjuvants, we should have used a different experimental set-up 
with additional lower/suboptimal concentrations of SLP. Most 
importantly, however, regardless of adjuvants and fundamen-
tal to our proof-of-concept, SLP consistently augmented HBV-
specific T-cell numbers as well as functional CD4+ and CD8+ T 
cells. In particular, the production of TNF-α and IFN-γ is highly 
relevant in the context of CHB, because noncytolytic mecha-
nisms are considered to be the most important mechanism by 
which CD8+ cells can suppress HBV and these cytokines are 
known to suppress HBV replication [35–38]. With respect to 
the coapplication of SLP with adjuvants, we would finally like 
to note that these in vitro experiments likely favor amplification 
of existing memory T-cell responses, which will respond much 
more rapidly and outcompete naive responses. In vivo, how-
ever, the vaccine may also prime naive T-cell response for which 
adjuvants will be crucial. As said, at the risk of inducing toler-
ance, SLP in the setting of HBV would never be applied without 
adjuvant. Our experiments so far do not argue in favor of one of 
the adjuvants tested, but it will be interesting to further investi-
gate the additive effect of adjuvants on T-cell function and also 
on naive T-cell priming to identify clearly the optimal adjuvant 
for SLP vaccination. Strategies such as combining adjuvants in 
one regimen and conjugation of adjuvants to SLP should also be 
considered in future study to enhance SLP-triggered immune 
responses, especially in vivo [12].
Patient selection in the present study was performed on 
mostly HBeAg negative patients under antiviral treatment 
because low viral load and serum ALT levels may favor the 
CD8+ T-cell response, DC function as well as the function of 
other immune cells [14, 15, 26, 39–42]. These patients likely suf-
fer least from the suppressive immune context found in CHB 
patients and thus would be the most interesting patient group 
for therapeutic vaccination. As demonstrated here, BDCA1+ 
mDC isolated from these patients are as effective as mDC 
isolated from healthy controls with respect to cross-presenta-
tion and induction of T-cell responses.
Nevertheless, despite the selection as described above, the 
immune system may still suffer from chronic infection and 
continuous antigen exposure such as T-cell exhaustion [27, 43]. 
We demonstrate that PD-1/PD-L1 blockade synergized in some 
patients with SLP stimulation. Due to the limited number of 
available samples, we could not identify any factors that could 
predict benefit of checkpoint blockade. Our results add to pre-
vious reports that PD-1/PD-L1 blockade can partly restore 
intrahepatic HBV-specific T-cell responses in vitro in CHB 
patients [20]. Targeting the PD-1 pathway may thus be an ad-
ditional component in a multifactorial approach, combining 
immune modulation, vaccination, and antiviral treatment, to 
restore the HBV directed T-cell response [44].
To summarize, we demonstrated that SLP vaccination rep-
resents an attractive treatment modality to trigger broad mul-
tifunctional HBV-specific T-cell responses in many HBV 
patients. This proof of concept paves the way for further de-
velopment of an SLP-based vaccine to treat CHB patients. 
Careful SLP design to include CD4 and CD8 T-cell epitopes for 
the most prevalent HLA types and combination of several SLP, 
covering multiple viral proteins in one vaccine, should warrant 
the induction of polyclonal and long lasting T-cell responses in 
many individuals.
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